NSCLC FOR PHASE 2 DOSE EXPANSION

Clinical trials for NSCLC FOR PHASE 2 DOSE EXPANSION explained in plain language.

Never miss a new study

Get alerted when new NSCLC FOR PHASE 2 DOSE EXPANSION trials appear

Sign up with your email to follow new studies for NSCLC FOR PHASE 2 DOSE EXPANSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New Triple-Threat cancer therapy shows early promise

Disease control Completed

This study tested new combinations of three immunotherapy drugs (surzebiclimab, alcestobart, and tislelizumab) in people with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find safe doses and see early signs that the treatments c…

Matched conditions: NSCLC FOR PHASE 2 DOSE EXPANSION

Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control

Last updated Apr 03, 2026 14:43 UTC

NSCLC FOR PHASE 2 DOSE EXPANSION

Get alerted when new NSCLC FOR PHASE 2 DOSE EXPANSION trials appear

New Triple-Threat cancer therapy shows early promise